




RealRate

PHARMACEUTICAL 2018

Eterna Therapeutics Inc. Rank 199 of 342





RealRate

PHARMACEUTICAL 2018

Eterna Therapeutics Inc. Rank 199 of 342



The relative strengths and weaknesses of Eterna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eterna Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Eterna Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 62%, being 16% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	9,638
Cost of Goods Sold	0
Intangible Assets	1,004
Liabilities, Current	10,747
Liabilities, Non-Current	52
Other Assets	2,250
Other Compr. Net Income	122
Other Expenses	7,155
Other Liabilities	235
Other Net Income	391
Other Revenues	21,274
Property and Equipment	3,678
Research and Development	0
Selling, General and Administrative Expense	15,587

Output Variable	Value in 1000 USD
Assets	16,570
Liabilities	11,034
Expenses	22,742
Revenues	21,274
Stockholders Equity	5,536
Net Income	-1,077
Comprehensive Net Income	-1,016
Economic Capital Ratio	62%